{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:40:40Z","timestamp":1793328040561,"version":"4.5.0"},"reference-count":204,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41582-019-0203-3","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:02:43Z","timestamp":1559228563000},"page":"373-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":364,"title":["Therapeutic developments for Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-7989","authenticated-orcid":false,"given":"Ingrid E. C.","family":"Verhaart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-654X","authenticated-orcid":false,"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"203_CR1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H. Jr & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","journal-title":"Cell"},{"key":"203_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.23810","volume":"48","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. & Lloyd-Puryear, M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 48, 21\u201326 (2013).","journal-title":"Muscle Nerve"},{"key":"203_CR3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AE Emery","year":"2002","unstructured":"Emery, A. E. The muscular dystrophies. Lancet 359, 687\u2013695 (2002).","journal-title":"Lancet"},{"key":"203_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant, D. J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 17, 251\u2013267 (2018).","journal-title":"Lancet Neurol."},{"key":"203_CR5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant, D. J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 17, 347\u2013361 (2018).","journal-title":"Lancet Neurol."},{"key":"203_CR6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant, D. J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 17, 445\u2013455 (2018).","journal-title":"Lancet Neurol."},{"key":"203_CR7","first-page":"CD003725","volume":"5","author":"E Matthews","year":"2016","unstructured":"Matthews, E., Brassington, R., Kuntzer, T., Jichi, F. & Manzur, A. Y. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 5, CD003725 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"203_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald, C. M. et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391, 451\u2013461 (2018).","journal-title":"Lancet"},{"key":"203_CR9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","volume":"15","author":"V Straub","year":"2016","unstructured":"Straub, V. et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the\u00a0example of Duchenne muscular dystrophy. Lancet Neurol. 15, 882\u2013890 (2016).","journal-title":"Lancet Neurol."},{"key":"203_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2014.11.011","volume":"25","author":"M Haas","year":"2015","unstructured":"Haas, M. et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul. Disord. 25, 5\u201313 (2015).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR11","unstructured":"U.S. Food & Drug Administration. FDA news release: FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. FDA https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm (updated 29 Sep 2016)."},{"key":"203_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-7374-3_1","volume":"1687","author":"JK Mah","year":"2018","unstructured":"Mah, J. K. An overview of recent therapeutics advances for Duchenne muscular dystrophy. Methods Mol. Biol. 1687, 3\u201317 (2018).","journal-title":"Methods Mol. Biol."},{"key":"203_CR13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/088307388900400402","volume":"4","author":"V Dubowitz","year":"1989","unstructured":"Dubowitz, V. The Duchenne dystrophy story: from phenotype to gene and potential treatment. J. Child Neurol. 4, 240\u2013250 (1989).","journal-title":"J. Child Neurol."},{"key":"203_CR14","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"DS Duan","year":"2018","unstructured":"Duan, D. S. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26, 2337\u20132356 (2018).","journal-title":"Mol. Ther."},{"key":"203_CR15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. & Kunkel, L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90\u201395 (1988).","journal-title":"Genomics"},{"key":"203_CR16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"SB England","year":"1990","unstructured":"England, S. B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180\u2013182 (1990).","journal-title":"Nature"},{"key":"203_CR17","unstructured":"Pfizer Inc. Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy. Pfizer https:\/\/press.pfizer.com\/press-release\/pfizer-doses-first-patient-using-investigational-mini-dystrophin-gene-therapy-treatmen (2018)."},{"key":"203_CR18","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03368742 (2017)."},{"key":"203_CR19","unstructured":"Solid Biosciences Inc. Press release: Solid Biosciences announces clinical hold on SGT-001 phase I\/II clinical trial for Duchenne muscular dystrophy. Solid Biosciences https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-clinical-hold-on-sgt-001-phase-i-ii-clinical-trial-for-duchenne-muscular-dystrophy (2018)."},{"key":"203_CR20","unstructured":"Solid Biosciences Inc. Insights: letter to the Duchenne community about the status of the IGNITE DMD clinical trial. Solid Biosciences https:\/\/www.solidbio.com\/about\/media\/news\/letter-to-the-duchenne-community-about-the-status-of-the-ignite-dmd-clinical-trial (2018)."},{"key":"203_CR21","unstructured":"Solid Biosciences Inc. Press release: Solid Biosciences announces FDA removes clinical hold on SGT-001. Solid Biosciences https:\/\/www.solidbio.com\/content\/solid-biosciences-announces-fda-removes-clinical-hold-sgt-001 (2018)."},{"key":"203_CR22","unstructured":"Solid Biosciences Inc. Press release: Solid Biosciences announces preliminary SGT-001 data and intention to dose escalate in IGNITE DMD clinical trial for Duchenne muscular dystrophy. Solid Biosciences https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-preliminary-sgt-001-data-and-intention-to-dose-escalate-in-ignite-dmd-clinical-trial-for-duchenne-muscular-dystrophy-1 (2019)."},{"key":"203_CR23","unstructured":"Sarepta Therapeutics Inc. Sarepta Therapeutics announces that at the 23rd international congress of the World Muscle Society, Jerry Mendell, M. D., presented positive updated results from the four children dosed in the gene therapy micro-dystrophin trial to treat patients with Duchenne muscular dystrophy. Sarepta Therapeutics http:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-23rd-international-congress-world (2018)."},{"key":"203_CR24","unstructured":"Sarepta Therapeutics Inc. Sarepta announces clinical hold lifted for its Duchenne muscular dystrophy micro-dystrophin gene therapy program. Sarepta Therapeutics http:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-announces-clinical-hold-lifted-its-duchenne-muscular (2018)."},{"key":"203_CR25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3233\/JND-180324","volume":"5","author":"H Gordish-Dressman","year":"2018","unstructured":"Gordish-Dressman, H. et al. \u201cOf mice and measures\u201d: a project to improve how we advance Duchenne muscular dystrophy therapies to the clinic. J. Neuromuscul. Dis. 5, 407\u2013417 (2018).","journal-title":"J. Neuromuscul. Dis."},{"key":"203_CR26","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-017-0124-z","volume":"7","author":"JN Kornegay","year":"2017","unstructured":"Kornegay, J. N. The golden retriever model of Duchenne muscular dystrophy. Skelet. Muscle 7, 9 (2017).","journal-title":"Skelet. Muscle"},{"key":"203_CR27","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1038\/mt.2012.181","volume":"20","author":"A Vulin","year":"2012","unstructured":"Vulin, A. et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol. Ther. 20, 2120\u20132133 (2012).","journal-title":"Mol. Ther."},{"key":"203_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.03.004","author":"C Leborgne","year":"2018","unstructured":"Leborgne, C. et al. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne muscular dystrophy patients. Cell. Immunol. https:\/\/doi.org\/10.1016\/j.cellimm.2018.03.004 (2018).","journal-title":"Cell. Immunol."},{"key":"203_CR29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","volume":"25","author":"A Majowicz","year":"2017","unstructured":"Majowicz, A. et al. Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5(ch) and AAV1. Mol. Ther. 25, 1831\u20131842 (2017).","journal-title":"Mol. Ther."},{"key":"203_CR30","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010).","journal-title":"N. Engl. J. Med."},{"key":"203_CR31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus, A. et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293\u2013299 (2009).","journal-title":"Hum. Mutat."},{"key":"203_CR32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen, C. L. et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"203_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. & Krieg, A. M. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. 27, 1\u20133 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"203_CR34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","volume":"14","author":"A Aartsma-Rus","year":"2018","unstructured":"Aartsma-Rus, A. & Arechavala-Gomeza, V. Why dystrophin quantification is key in the eteplirsen saga. Nat. Rev. Neurol. 14, 454\u2013456 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"203_CR35","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy. Neurology 90, e2146\u2013e2154 (2018).","journal-title":"Neurology"},{"key":"203_CR36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257\u2013271 (2016).","journal-title":"Ann. Neurol."},{"key":"203_CR37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/nat.2018.0756","volume":"29","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus, A. & Goemans, N. A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid Ther. 29, 13\u201315 (2019).","journal-title":"Nucleic Acid Ther."},{"key":"203_CR38","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans, N. M. et al. Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 364, 1513\u20131522 (2011).","journal-title":"N. Engl. J. Med."},{"key":"203_CR39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","volume":"28","author":"N Goemans","year":"2018","unstructured":"Goemans, N. et al. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul. Disord. 28, 4\u201315 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","volume":"13","author":"T Voit","year":"2014","unstructured":"Voit, T. et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 13, 987\u2013996 (2014).","journal-title":"Lancet Neurol."},{"key":"203_CR41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/acn3.579","volume":"5","author":"CM McDonald","year":"2018","unstructured":"McDonald, C. M. et al. Placebo-controlled phase 2 trial of drisapersen for Duchenne muscular dystrophy. Ann. Clin. Transl Neurol. 5, 913\u2013926 (2018).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"203_CR42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto, N. et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 35, 845\u2013851 (2017).","journal-title":"Nat. Biotechnol."},{"key":"203_CR43","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03508947 (2019)."},{"key":"203_CR44","volume":"2","author":"H Yin","year":"2013","unstructured":"Yin, H. et al. Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency. Mol. Ther. Nucleic Acids 2, e124 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"203_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/nat.2013.0448","volume":"24","author":"SM Jirka","year":"2014","unstructured":"Jirka, S. M. et al. Peptide conjugation of 2\u2032-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice. Nucleic Acid Ther. 24, 25\u201336 (2014).","journal-title":"Nucleic Acid Ther."},{"key":"203_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymthe.2017.10.004","volume":"26","author":"SMG Jirka","year":"2018","unstructured":"Jirka, S. M. G. et al. Cyclic peptides to improve delivery and exon skipping of antisense oligonucleotides in a mouse model for Duchenne muscular dystrophy. Mol.\u00a0Ther. 26, 132\u2013147 (2018).","journal-title":"Mol. Ther."},{"key":"203_CR47","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/cvr\/cvp335","volume":"85","author":"N Jearawiriyapaisarn","year":"2010","unstructured":"Jearawiriyapaisarn, N., Moulton, H. M., Sazani, P., Kole, R. & Willis, M. S. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc. Res. 85, 444\u2013453 (2010).","journal-title":"Cardiovasc. Res."},{"key":"203_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts, C. et al. Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids 1, e38 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"203_CR49","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya, Y. et al. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc. Natl Acad. Sci. USA 114, 4213\u20134218 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"203_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2018.0747","volume":"29","author":"MJ Gait","year":"2019","unstructured":"Gait, M. J. et al. Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucleic Acid. Ther. 29, 1\u201312 (2019).","journal-title":"Nucleic Acid. Ther."},{"key":"203_CR51","volume":"5","author":"Q Li","year":"2017","unstructured":"Li, Q., Xu, M., Cui, Y., Huang, C. & Sun, M. Arginine-rich membrane-permeable peptides are seriously toxic. Pharmacol. Res. Perspect. 5, e00334 (2017).","journal-title":"Pharmacol. Res. Perspect."},{"key":"203_CR52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. et al. Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther. 27, 251\u2013259 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"203_CR53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/jpm8040038","volume":"8","author":"KRQ Lim","year":"2018","unstructured":"Lim, K. R. Q., Yoon, C. & Yokota, T. Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy. J. Pers. Med. 8, 38 (2018).","journal-title":"J. Pers. Med."},{"key":"203_CR54","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson, N. E. et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun. 8, 14454 (2017).","journal-title":"Nat. Commun."},{"key":"203_CR55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.117.310996","volume":"121","author":"M El Refaey","year":"2017","unstructured":"El Refaey, M. et al. In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice. Circ. Res. 121, 923\u2013929 (2017).","journal-title":"Circ. Res."},{"key":"203_CR56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.molmed.2016.01.007","volume":"22","author":"DU Kemaladewi","year":"2016","unstructured":"Kemaladewi, D. U. & Cohn, R. D. Exon snipping in Duchenne muscular dystrophy. Trends Mol. Med. 22, 187\u2013189 (2016).","journal-title":"Trends Mol. Med."},{"key":"203_CR57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400\u2013403 (2016).","journal-title":"Science"},{"key":"203_CR58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407 (2016).","journal-title":"Science"},{"key":"203_CR59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411 (2016).","journal-title":"Science"},{"key":"203_CR60","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/mt.2015.192","volume":"24","author":"L Xu","year":"2016","unstructured":"Xu, L. et al. CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol. Ther. 24, 564\u2013569 (2016).","journal-title":"Mol. Ther."},{"key":"203_CR61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124297","volume":"3","author":"CH Hakim","year":"2018","unstructured":"Hakim, C. H. et al. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight 3, e124297 (2018).","journal-title":"JCI Insight"},{"key":"203_CR62","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","volume":"26","author":"BL Duch\u00eane","year":"2018","unstructured":"Duch\u00eane, B. L. et al. CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo. Mol. Ther. 26, 2604\u20132616 (2018).","journal-title":"Mol. Ther."},{"key":"203_CR63","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout, D. G. et al. Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 6, 6244 (2015).","journal-title":"Nat. Commun."},{"key":"203_CR64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young, C. S. et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18, 533\u2013540 (2016).","journal-title":"Cell Stem Cell"},{"key":"203_CR65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii, L. et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362, 86\u201390 (2018).","journal-title":"Science"},{"key":"203_CR66","volume":"6","author":"I Maggio","year":"2016","unstructured":"Maggio, I., Liu, J., Janssen, J. M., Chen, X. & Goncalves, M. A. Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells. Sci.\u00a0Rep. 6, 37051 (2016).","journal-title":"Sci. Rep."},{"key":"203_CR67","doi-asserted-by":"crossref","first-page":"14038","DOI":"10.1038\/mtm.2014.38","volume":"1","author":"AL Arnett","year":"2014","unstructured":"Arnett, A. L. et al. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol. Ther. Methods Clin. Dev. 1, 14038 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"203_CR68","doi-asserted-by":"crossref","first-page":"27439","DOI":"10.1039\/C8CP04226H","volume":"20","author":"L Zheng","year":"2018","unstructured":"Zheng, L., Shi, J. & Mu, Y. Dynamics changes of CRISPR-Cas9 systems induced by high fidelity mutations. Phys. Chem. Chem. Phys. 20, 27439\u201327448 (2018).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"203_CR69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","volume":"25","author":"CE Nelson","year":"2019","unstructured":"Nelson, C. E. et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat. Med. 25, 427\u2013432 (2019).","journal-title":"Nat. Med."},{"key":"203_CR70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1126\/science.aab1028","volume":"348","author":"D Baltimore","year":"2015","unstructured":"Baltimore, D. et al. A prudent path forward for genomic engineering and germline gene modification. Science 348, 36\u201338 (2015).","journal-title":"Science"},{"key":"203_CR71","unstructured":"Committee on Science, Technology, and Law Policy and Global Affairs. International Summit on Human Gene Editing: A Global Discussion (National Academies Press, 2015)."},{"key":"203_CR72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus, A., Ginjaar, I. B. & Bushby, K. The\u00a0importance of genetic diagnosis for Duchenne muscular dystrophy. J. Med. Genet. 53, 145\u2013151 (2016).","journal-title":"J. Med. Genet."},{"key":"203_CR73","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","volume":"67","author":"V Malik","year":"2010","unstructured":"Malik, V. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 67, 771\u2013780 (2010).","journal-title":"Ann. Neurol."},{"key":"203_CR74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/ijmm.2014.1809","volume":"34","author":"J Karijolich","year":"2014","unstructured":"Karijolich, J. & Yu, Y. T. Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review). Int. J. Mol. Med. 34, 355\u2013362 (2014).","journal-title":"Int. J. Mol. Med."},{"key":"203_CR75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch, E. M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87\u201391 (2007).","journal-title":"Nature"},{"key":"203_CR76","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby, K. et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50, 477\u2013487 (2014).","journal-title":"Muscle Nerve"},{"key":"203_CR77","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald, C. M. et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1489\u20131498 (2017).","journal-title":"Lancet"},{"key":"203_CR78","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03648827 (2019)."},{"key":"203_CR79","unstructured":"PTC Therapeutics. PTC Therapeutics announces initial data from patient registry demonstrating Translarna\u2122 (ataluren) slows disease progression in children with Duchenne caused by a nonsense mutation. PTC Therapeutics http:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-announces-initial-data-patient-registry (2018)."},{"key":"203_CR80","unstructured":"PTC Therapeutics. CHMP adopts positive opinion for the expansion of the Translarna\u2122 (ataluren) label to include patients as young as 2 years of age. PTC Therapeutics http:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/chmp-adopts-positive-opinion-expansion-translarnatm-ataluren (2018)."},{"key":"203_CR81","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/14712598.2015.1057564","volume":"15","author":"D Skuk","year":"2015","unstructured":"Skuk, D. & Tremblay, J. P. Cell therapy in muscular dystrophies: many promises in mice and dogs, few facts in patients. Expert Opin. Biol. Ther. 15, 1307\u20131319 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"203_CR82","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.15252\/emmm.201505636","volume":"7","author":"G Cossu","year":"2015","unstructured":"Cossu, G. et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol. Med. 7, 1513\u20131528 (2015).","journal-title":"EMBO Mol. Med."},{"key":"203_CR83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.jnen.0000218443.45782.81","volume":"65","author":"D Skuk","year":"2006","unstructured":"Skuk, D. et al. Dystrophin expression in muscles of Duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J.\u00a0Neuropathol. Exp. Neurol. 65, 371\u2013386 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"203_CR84","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ymthe.2003.11.023","volume":"9","author":"D Skuk","year":"2004","unstructured":"Skuk, D. et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol. Ther. 9, 475\u2013482 (2004).","journal-title":"Mol. Ther."},{"key":"203_CR85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nmd.2006.10.003","volume":"17","author":"D Skuk","year":"2007","unstructured":"Skuk, D. et al. First test of a \u201chigh-density injection\u201d protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul. Disord. 17, 38\u201346 (2007).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR86","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.15252\/emmm.201607129","volume":"8","author":"G Cossu","year":"2016","unstructured":"Cossu, G. et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol. Med. 8, 1470\u20131471 (2016).","journal-title":"EMBO Mol. Med."},{"key":"203_CR87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","volume":"29","author":"J Vandewalle","year":"2018","unstructured":"Vandewalle, J., Luypaert, A., De Bosscher, K. & Libert, C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol. Metab. 29, 42\u201354 (2018).","journal-title":"Trends Endocrinol. Metab."},{"key":"203_CR88","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/mol.107.038794","volume":"72","author":"R Newton","year":"2007","unstructured":"Newton, R. & Holden, N. S. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol. Pharmacol. 72, 799\u2013809 (2007).","journal-title":"Mol. Pharmacol."},{"key":"203_CR89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.112.194340","volume":"343","author":"AR Baudy","year":"2012","unstructured":"Baudy, A. R. et al. 9,11 modification of glucocorticoids dissociates nuclear factor-\u03baB inhibitory efficacy from glucocorticoid response element-associated side effects. J. Pharmacol. Exp. Ther. 343, 225\u2013232 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"203_CR90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","volume":"134","author":"EP Hoffman","year":"2018","unstructured":"Hoffman, E. P. et al. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134, 43\u201352 (2018).","journal-title":"Steroids"},{"key":"203_CR91","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"LS Conklin","year":"2018","unstructured":"Conklin, L. S. et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol. Res. 136, 140\u2013150 (2018).","journal-title":"Pharmacol. Res."},{"key":"203_CR92","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03038399 (2018)."},{"key":"203_CR93","unstructured":"Vision-DMD. Vision-DMD update on vamolorone. YouTube https:\/\/www.youtube.com\/watch?v=Ty1QMp5N5c8 (2018)."},{"key":"203_CR94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/eurheartj\/ehn406","volume":"30","author":"GM Buyse","year":"2009","unstructured":"Buyse, G. M. et al. Long-term blinded placebo-controlled study of SNT-MC17\/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur. Heart J. 30, 116\u2013124 (2009).","journal-title":"Eur. Heart J."},{"key":"203_CR95","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ppul.22688","volume":"48","author":"GM Buyse","year":"2013","unstructured":"Buyse, G. M., Goemans, N., van den Hauwe, M. & Meier, T. Effects of glucocorticoids and idebenone on respiratory function in patients with Duchenne muscular dystrophy. Pediatr. Pulmonol. 48, 912\u2013920 (2013).","journal-title":"Pediatr. Pulmonol."},{"key":"203_CR96","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","volume":"385","author":"GM Buyse","year":"2015","unstructured":"Buyse, G. M. et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 385, 1748\u20131757 (2015).","journal-title":"Lancet"},{"key":"203_CR97","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2016.05.008","volume":"26","author":"CM McDonald","year":"2016","unstructured":"McDonald, C. M. et al. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscul. Disord. 26, 473\u2013480 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR98","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.nmd.2016.12.014","volume":"27","author":"T Meier","year":"2017","unstructured":"Meier, T. et al. Characterization of pulmonary function in 10\u201318 year old patients with Duchenne muscular dystrophy. Neuromuscul. Disord. 27, 307\u2013314 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR99","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. EMA https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-duchenne-becker-muscular-dystrophy_en.pdf (2015)."},{"key":"203_CR100","unstructured":"Santhera Pharmaceuticals Holding. Santhera receives negative CHMP opinion on appeal for authorization of Raxone\u00ae in Duchenne muscular dystrophy. Santhera https:\/\/www.santhera.com\/assets\/files\/press-releases\/2018-01-26_CHMP-appeal_e_finalx.pdf (2018)."},{"key":"203_CR101","doi-asserted-by":"crossref","DOI":"10.1186\/2044-5040-3-9","volume":"3","author":"JP Ennen","year":"2013","unstructured":"Ennen, J. P., Verma, M. & Asakura, A. Vascular-targeted therapies for Duchenne muscular dystrophy. Skelet. Muscle 3, 9 (2013).","journal-title":"Skelet. Muscle"},{"key":"203_CR102","first-page":"914","volume":"28","author":"NW Dombernowsky","year":"2018","unstructured":"Dombernowsky, N. W., Olmestig, J. N. E., Witting, N. & Kruuse, C. Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies \u2014 still a possible treatment modality? Neuromuscul. Disord. 28, 914\u2013926 (2018).","journal-title":"Disord."},{"key":"203_CR103","doi-asserted-by":"crossref","first-page":"162ra155","DOI":"10.1126\/scitranslmed.3004327","volume":"4","author":"EA Martin","year":"2012","unstructured":"Martin, E. A. et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci. Transl Med. 4, 162ra155 (2012).","journal-title":"Sci. Transl Med."},{"key":"203_CR104","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.24216","volume":"76","author":"N Witting","year":"2014","unstructured":"Witting, N. et al. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. Ann. Neurol. 76, 550\u2013557 (2014).","journal-title":"Ann. Neurol."},{"key":"203_CR105","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/WNL.0000000000000498","volume":"82","author":"MD Nelson","year":"2014","unstructured":"Nelson, M. D. et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82, 2085\u20132091 (2014).","journal-title":"Neurology"},{"key":"203_CR106","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","volume":"76","author":"DG Leung","year":"2014","unstructured":"Leung, D. G. et al. Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy. Ann. Neurol. 76, 541\u2013549 (2014).","journal-title":"Ann. Neurol."},{"key":"203_CR107","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2006.08.028","volume":"1118","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 1118, 192\u2013198 (2006).","journal-title":"Brain Res."},{"key":"203_CR108","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","volume":"89","author":"RG Victor","year":"2017","unstructured":"Victor, R. G. et al. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology 89, 1811\u20131820 (2017).","journal-title":"Neurology"},{"key":"203_CR109","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1007\/s00018-014-1689-x","volume":"71","author":"J Rodriguez","year":"2014","unstructured":"Rodriguez, J. et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell.\u00a0Mol. Life Sci. 71, 4361\u20134371 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"203_CR110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ana.10385","volume":"52","author":"KR Wagner","year":"2002","unstructured":"Wagner, K. R., McPherron, A. C., Winik, N. & Lee, S. J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann. Neurol. 52, 832\u2013836 (2002).","journal-title":"Ann. Neurol."},{"key":"203_CR111","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.2353\/ajpath.2010.090932","volume":"176","author":"KT Murphy","year":"2010","unstructured":"Murphy, K. T. et al. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am. J. Pathol. 176, 2425\u20132434 (2010).","journal-title":"Am. J. Pathol."},{"key":"203_CR112","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpdd.386","volume":"7","author":"I Bhattacharya","year":"2018","unstructured":"Bhattacharya, I. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects. Clin. Pharmacol. Drug Dev. 7, 484\u2013497 (2018).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"203_CR113","unstructured":"Pfizer Inc. Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy. Pfizer https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy (2018)."},{"key":"203_CR114","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02515669 (2018)."},{"key":"203_CR115","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.nmd.2018.06.151","volume":"28","author":"K Wagner","year":"2018","unstructured":"Wagner, K. et al. DMD clinical therapies I. Neuromuscul. Disord. 28, S66 (2018).","journal-title":"DMD clinical therapies I. Neuromuscul. Disord."},{"key":"203_CR116","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ajpath.2010.11.071","volume":"178","author":"EE Pistilli","year":"2011","unstructured":"Pistilli, E. E. et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178, 1287\u20131297 (2011).","journal-title":"Am. J. Pathol."},{"key":"203_CR117","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell, C. et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55, 458\u2013464 (2017).","journal-title":"Muscle Nerve"},{"key":"203_CR118","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","volume":"98","author":"SJ Lee","year":"2001","unstructured":"Lee, S. J. & McPherron, A. C. Regulation of myostatin activity and muscle growth. Proc. Natl Acad. Sci. USA 98, 9306\u20139311 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"203_CR119","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajpath.2011.04.008","volume":"179","author":"J Zhu","year":"2011","unstructured":"Zhu, J. et al. Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. Am. J. Pathol. 179, 915\u2013930 (2011).","journal-title":"Am. J. Pathol."},{"key":"203_CR120","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1089\/hum.2011.102","volume":"22","author":"LT Bish","year":"2011","unstructured":"Bish, L. T. et al. Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy. Hum. Gene Ther. 22, 1499\u20131509 (2011).","journal-title":"Hum. Gene Ther."},{"key":"203_CR121","doi-asserted-by":"crossref","first-page":"6ra15","DOI":"10.1126\/scitranslmed.3000112","volume":"1","author":"J Kota","year":"2009","unstructured":"Kota, J. et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci. Transl Med. 1, 6ra15 (2009).","journal-title":"Sci. Transl Med."},{"key":"203_CR122","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","volume":"23","author":"JR Mendell","year":"2015","unstructured":"Mendell, J. R. et al. A phase 1\/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol. Ther. 23, 192\u2013201 (2015).","journal-title":"Mol. Ther."},{"key":"203_CR123","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02354781 (2017)."},{"key":"203_CR124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","volume":"19","author":"S Consalvi","year":"2013","unstructured":"Consalvi, S. et al. Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol. Med. 19, 79\u201387 (2013).","journal-title":"Mol. Med."},{"key":"203_CR125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica, P. et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 26, 643\u2013649 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR126","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02851797 (2019)."},{"key":"203_CR127","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pmr.2011.11.014","volume":"23","author":"JN Kornegay","year":"2012","unstructured":"Kornegay, J. N. et al. The paradox of muscle hypertrophy in muscular dystrophy. Phys. Med. Rehabil. Clin. N. Am. 23, 149\u2013172 (2012).","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"203_CR128","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-016-0085-7","volume":"6","author":"JN Kornegay","year":"2016","unstructured":"Kornegay, J. N. et al. Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. Skelet. Muscle 6, 14 (2016).","journal-title":"Skelet. Muscle"},{"key":"203_CR129","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot, V. et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat. Commun. 8, 1859 (2017).","journal-title":"Nat. Commun."},{"key":"203_CR130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00415-016-8379-6","volume":"264","author":"PM Burch","year":"2017","unstructured":"Burch, P. M. et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. J. Neurol. 264, 541\u2013553 (2017).","journal-title":"J. Neurol."},{"key":"203_CR131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omtn.2016.11.009","volume":"6","author":"N Lu-Nguyen","year":"2017","unstructured":"Lu-Nguyen, N. et al. Systemic antisense therapeutics for dystrophin and myostatin exon splice modulation improve muscle pathology of adult mdx mice. Mol.\u00a0Ther. Nucleic Acids 6, 15\u201328 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"203_CR132","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.nmd.2018.05.013","volume":"28","author":"V Straub","year":"2018","unstructured":"Straub, V., Mercuri, E. & DMD outcome measure study group. Report on the workshop: meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30\u201331 January 2017. Neuromuscul. Disord. 28, 690\u2013701 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"203_CR133","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","volume":"53","author":"M Koenig","year":"1988","unstructured":"Koenig, M., Monaco, A. P. & Kunkel, L. M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219\u2013228 (1988).","journal-title":"Cell"},{"key":"203_CR134","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02500381 (2019)."},{"key":"203_CR135","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.nmd.2017.06.440","volume":"27","author":"K Takaishi","year":"2017","unstructured":"Takaishi, K. et al. Stunning pharmacological properties of DS-5141b, an antisense oligonucleotide consisting of 2\u2032-O,4\u2032-C-ethylene-bridged nucleic acids and 2\u2032-O-methyl RNA, on dystrophin mRNA exon skipping. Neuromuscul. Disord. 27, S216\u2013S216 (2017).","journal-title":"RNA, on dystrophin mRNA exon skipping. Neuromuscul. Disord."},{"key":"203_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02667483 (2019)."},{"key":"203_CR137","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02255552 (2018)."},{"key":"203_CR138","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03218995 (2018)."},{"key":"203_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02310906 (2019)."},{"key":"203_CR140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","volume":"10","author":"H Komaki","year":"2018","unstructured":"Komaki, H. et al. Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci. Transl Med. 10, eaan0713 (2018).","journal-title":"Sci. Transl Med."},{"key":"203_CR141","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02740972 (2018)."},{"key":"203_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03375255 (2018)."},{"key":"203_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03179631 (2019)."},{"key":"203_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02369731 (2017)."},{"key":"203_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03362502 (2019)."},{"key":"203_CR146","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03375164 (2018)."},{"key":"203_CR147","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03769116 (2019)."},{"key":"203_CR148","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02196467 (2018)."},{"key":"203_CR149","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.22047","volume":"44","author":"CF Spurney","year":"2011","unstructured":"Spurney, C. F. et al. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 44, 174\u2013178 (2011).","journal-title":"Muscle Nerve"},{"key":"203_CR150","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01126697 (2018)."},{"key":"203_CR151","unstructured":"Akashi Therapeutics. Dosing and enrollment in HT-100 trial suspended. Akashi Therapeutics https:\/\/akashirx.com\/news\/dosing-and-enrollment-in-ht-100-trial-suspended\/ (2016)."},{"key":"203_CR152","first-page":"135","volume":"26","author":"M Pines","year":"2011","unstructured":"Pines, M. & Halevy, O. Halofuginone and muscular dystrophy. Histol. Histopathol. 26, 135\u2013146 (2011).","journal-title":"Histol. Histopathol."},{"key":"203_CR153","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","volume":"182","author":"OM Dorchies","year":"2013","unstructured":"Dorchies, O. M. et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 182, 485\u2013504 (2013).","journal-title":"Am. J. Pathol."},{"key":"203_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02835079 (2018)."},{"key":"203_CR155","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03354039 (2018)."},{"key":"203_CR156","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02606136 (2019)."},{"key":"203_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03373968 (2019)."},{"key":"203_CR158","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","volume":"58","author":"PB Shieh","year":"2018","unstructured":"Shieh, P. B. et al. Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post hoc analysis from the ACT DMD trial. Muscle Nerve 58, 639\u2013645 (2018).","journal-title":"Muscle Nerve"},{"key":"203_CR159","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01603407 (2018)."},{"key":"203_CR160","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03439670 (2019)."},{"key":"203_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1388","author":"PD Mavroudis","year":"2019","unstructured":"Mavroudis, P. D. et al. Population pharmacokinetics of vamorolone (VBP15) in healthy men and boys with Duchenne muscular dystrophy. J. Clin. Pharmacol. https:\/\/doi.org\/10.1002\/jcph.1388 (2019).","journal-title":"J. Clin. Pharmacol."},{"key":"203_CR162","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jcph.842","volume":"57","author":"JM Donovan","year":"2017","unstructured":"Donovan, J. M., Zimmer, M., Offman, E., Grant, T. & Jirousek, M. A novel NF-\u03baB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J. Clin. Pharmacol. 57, 627\u2013639 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"203_CR163","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JND-180341","volume":"6","author":"E Finanger","year":"2019","unstructured":"Finanger, E. et al. Phase 1 study of edasalonexent (CAT-1004), an oral NF-\u03baB inhibitor, in pediatric patients with Duchenne muscular dystrophy. J.\u00a0Neuromuscul. Dis. 6, 43\u201354 (2019).","journal-title":"J. Neuromuscul. Dis."},{"key":"203_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02439216 (2018)."},{"key":"203_CR165","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03703882 (2019)."},{"key":"203_CR166","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03400852 (2019)."},{"key":"203_CR167","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.expneurol.2009.09.015","volume":"220","author":"S Messina","year":"2009","unstructured":"Messina, S. et al. Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone. Exp. Neurol. 220, 349\u2013358 (2009).","journal-title":"Exp. Neurol."},{"key":"203_CR168","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01335295 (2014)."},{"key":"203_CR169","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1016\/j.nmd.2017.06.445","volume":"27","author":"H Komaki","year":"2017","unstructured":"Komaki, H. et al. A phase I, single- and repeated-dose study of TAS-205, a novel inhibitor of hematopoietic prostaglandin D synthase, in patients with Duchenne muscular dystrophy. Neuromuscul. Dis. 27, S218\u2013S218 (2017).","journal-title":"Neuromuscul. Dis."},{"key":"203_CR170","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02752048 (2019)."},{"key":"203_CR171","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"M St Andre","year":"2017","unstructured":"St Andre, M. et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet. Muscle 7, 25 (2017).","journal-title":"Skelet. Muscle"},{"key":"203_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03039686 (2019)."},{"key":"203_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02814019 (2018)."},{"key":"203_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03603288 (2019)."},{"key":"203_CR175","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02710591 (2018)."},{"key":"203_CR176","doi-asserted-by":"publisher","DOI":"10.1371\/currents.md.2cc69a1dae4be7dfe2bcb420024ea865","author":"HD Allen","year":"2013","unstructured":"Allen, H. D. et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy. PLOS Curr. https:\/\/doi.org\/10.1371\/currents.md.2cc69a1dae4be7dfe2bcb420024ea865 (2013).","journal-title":"PLOS Curr."},{"key":"203_CR177","volume":"11","author":"P Hafner","year":"2016","unstructured":"Hafner, P. et al. Improved muscle function in Duchenne muscular dystrophy through L-arginine and metformin: an investigator-initiated, open-label, single-center, proof-of-concept-study. PLOS ONE 11, e0147634 (2016).","journal-title":"PLOS ONE"},{"key":"203_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01995032 (2018)."},{"key":"203_CR179","unstructured":"Parent Project Muscular Dystrophy. Lilly trial finishes with disappointing results. PPMD http:\/\/community.parentprojectmd.org\/profiles\/blogs\/lilly-trial-finishes-with-disappointing-results (2016)."},{"key":"203_CR180","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0590-8","volume":"12","author":"SV Raman","year":"2017","unstructured":"Raman, S. V. et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial. Orphanet J. Rare Dis. 12, 39 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"203_CR181","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02354352 (2019)."},{"key":"203_CR182","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03777319 (2019)."},{"key":"203_CR183","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","volume":"92","author":"M Taylor","year":"2019","unstructured":"Taylor, M. et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology 92, e866\u2013e878 (2019).","journal-title":"Neurology"},{"key":"203_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03406780 (2019)."},{"key":"203_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00819845 (2016)."},{"key":"203_CR186","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2169\/internalmedicine.49.3259","volume":"49","author":"T Matsumura","year":"2010","unstructured":"Matsumura, T., Tamura, T., Kuru, S., Kikuchi, Y. & Kawai, M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern. Med. 49, 1357\u20131363 (2010).","journal-title":"Intern. Med."},{"key":"203_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03340675 (2019)."},{"key":"203_CR188","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2261-11-20","volume":"11","author":"CF Spurney","year":"2011","unstructured":"Spurney, C. F. et al. Membrane sealant poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC\u00a0Cardiovasc. Disord. 11, 20 (2011).","journal-title":"BMC Cardiovasc. Disord."},{"key":"203_CR189","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091221","volume":"9","author":"RL Terry","year":"2014","unstructured":"Terry, R. L., Kaneb, H. M. & Wells, D. J. Poloxamer [corrected] 188 has a deleterious effect on dystrophic skeletal muscle function. PLOS ONE 9, e91221 (2014).","journal-title":"PLOS ONE"},{"key":"203_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03558958 (2019)."},{"key":"203_CR191","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-015-0435-5","volume":"75","author":"J Fongemie","year":"2015","unstructured":"Fongemie, J. & Felix-Getzik, E. A review of nebivolol pharmacology and clinical evidence. Drugs 75, 1349\u20131371 (2015).","journal-title":"Drugs"},{"key":"203_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01648634 (2018)."},{"key":"203_CR193","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00418-012-0926-3","volume":"137","author":"Y Nakae","year":"2012","unstructured":"Nakae, Y. et al. Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea. Histochem. Cell Biol. 137, 811\u2013827 (2012).","journal-title":"Histochem. Cell Biol."},{"key":"203_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01183767 (2018)."},{"key":"203_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02964377 (2019)."},{"key":"203_CR196","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","volume":"23","author":"AM Sbrocchi","year":"2012","unstructured":"Sbrocchi, A. M. et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int. 23, 2703\u20132711 (2012).","journal-title":"Osteoporos Int."},{"key":"203_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00799266 (2018)."},{"key":"203_CR198","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine, L. G. et al. Vascular delivery of rAAVrh74. MCK. GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates. Mol. Ther. 22, 713\u2013724 (2014).","journal-title":"Mol. Ther."},{"key":"203_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03333590 (2018)."},{"key":"203_CR200","unstructured":"Summit Therapeutics Plc. Summit announces PhaseOut DMD did not meet primary endpoint. Summit Therapeutics https:\/\/www.summitplc.com\/app\/uploads\/2018\/09\/27-06-2018_RNS_30-PhaseOut-Full-Results-FINAL.pdf (2018)."},{"key":"203_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.642","author":"F Muntoni","year":"2019","unstructured":"Muntoni, F. et al. A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric Duchenne muscular dystrophy patients on a balanced diet. Clin. Pharmacol. Drug Dev. https:\/\/doi.org\/10.1002\/cpdd.642 (2019).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"203_CR202","volume":"11","author":"V Ricotti","year":"2016","unstructured":"Ricotti, V. et al. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with Duchenne muscular dystrophy. PLOS ONE 11, e0152840 (2016).","journal-title":"PLOS ONE"},{"key":"203_CR203","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0035-1563696","volume":"46","author":"CL Wood","year":"2015","unstructured":"Wood, C. L. et al. Testosterone treatment of pubertal delay in Duchenne muscular dystrophy. Neuropediatrics 46, 371\u2013376 (2015).","journal-title":"Neuropediatrics"},{"key":"203_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02571205 (2018)."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0203-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0203-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0203-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T21:59:34Z","timestamp":1721339974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-019-0203-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":204,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1038\/s41582-019-0203-3","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"30 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.-R. declares that she is named as an inventor on and receives royalties in relation to patents owned by her employer, Leiden University Medical Centre (LUMC), on exon-skipping technology, some of which have been licensed to BioMarin Pharmaceuticals and sublicensed to Sarepta. A.A.-R. also declares that she has acted as a consultant for BioClinica, BioMarin Pharmaceuticals, Eisai, Gerson Lehrman Group Consultancy, Global Guidepoint, Grunenthal, PTC Therapeutics, Sarepta and Wave and that she has been a member of the Duchenne Network Steering Committee for BioMarin and a member of the scientific advisory boards of Philae Pharmaceuticals and ProQR. Remuneration for these activities of A.A.-R., as well speaker\u2019s honoraria from PTC Therapeutics and BioMarin Pharmaceuticals, is paid to LUMC. I.E.C.V. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}